Table of Contents |
1. | New Trends in Psychoactive Drug Use | 1 |
1.1. | Introduction | 1 |
1.2. | Defining Emerging Drugs | 3 |
1.3. | Sources of Emerging Drugs | 5 |
1.4. | General Patterns of Use | 6 |
1.5. | Public Health Concerns | 7 |
1.6. | Divergence from Federal Guidance and Law | 9 |
1.7. | Setting the Tone | 10 |
| References | 10 |
2. | Emerging Drugs, Today Versus Yesteryear | 13 |
2.1. | Partitioning Recreational Drugs from Medicine | 13 |
2.1.1. | Absinthe | 14 |
2.1.2. | LSD | 18 |
2.1.3. | Quaalude | 21 |
2.1.4. | MDMA, Ketamine, and GHB | 23 |
2.2. | Drug Scares and the Media | 25 |
2.3. | Current Trends | 26 |
2.3.1. | Newly Synthesized Analogues | 26 |
2.3.2. | New to Us---Botanicals | 28 |
2.3.3. | New Tricks for Old Drugs | 29 |
2.4. | Connecting the Past to the Present | 30 |
| References | 31 |
3. | Emerging Drug Trade and Use: Manufacturing, Marketing, and Understanding Novel Highs | 33 |
3.1. | The Shadow Industry Profiting from Emerging Drug Use | 33 |
3.1.1. | Drug Development and the Regulate and Reformulate Game | 35 |
3.1.2. | Distribution and International Issues | 37 |
3.2. | The Sale and Marketing of Novel Drugs | 38 |
3.2.1. | Over the Counter Retail Sales | 38 |
3.2.2. | Street Dealers and Black Market Distribution | 39 |
3.2.3. | Online Sales | 40 |
3.3. | The Role of the Internet in the Spread of Emerging Drugs | 42 |
3.4. | Explaining Emerging Drug Use | 43 |
3.4.1. | Traditional Explanations of Drug Use | 44 |
3.4.2. | Emerging Drugs as Replacements for Banned Substances | 46 |
3.4.3. | Emerging Drug Use as a Deviant Social Milestone | 47 |
| References | 48 |
4. | Case Studies of Emerging Drugs: Salvia, Bath Salts, and Bromo-DragonFly | 53 |
4.1. | Case Study 1: Salvia divinorum | 53 |
4.1.1. | Historic Use of Salvia | 54 |
4.1.2. | Modern Salvia Use | 54 |
4.1.3. | Media Coverage and Regulation of Salvia | 55 |
4.1.4. | The Scope of Salvia Use | 56 |
4.1.5. | Salvia: An Internet Phenomenon? | 58 |
4.1.6. | Typology of Salvia Users | 59 |
4.1.7. | Lessons from Salvia Use in the USA | 61 |
4.2. | Case Study 2: Synthetic Stimulants Called "Bath Salts" | 61 |
4.2.1. | Bath Salts and the Body | 62 |
4.2.2. | The Emergence of Bath Salt Use | 63 |
4.2.3. | US Media and Cultural Panics Linked to Bath Salt Use | 65 |
4.2.4. | Regulation of Bath Salts and Results | 66 |
4.2.5. | Lessons from Bath Salts and the Future | 67 |
4.3. | Case Study 3: Bromo-DragonFly, a Powerful Hallucinogen | 68 |
| References | 70 |
5. | What Is Being Done About Emerging Drugs? | 75 |
5.1. | The Controlled Substances Act | 75 |
5.1.1. | Emergency Scheduling Powers | 76 |
5.1.2. | Controlled Substance Analogues | 77 |
5.1.3. | Food and Drug Administration | 78 |
5.2. | A Move Away from the CSA | 79 |
5.2.1. | State-Level Medicalization of Marijuana | 80 |
5.2.2. | Salvia divinorum, Kratom, and other State Level Bans | 80 |
5.3. | Synthetic Cannabinoids, Bath Salts, and the Synthetic Drug Abuse Prevention Act of 2012 | 83 |
5.4. | International Regulations of Emerging Drugs | 84 |
5.5. | Law Enforcement and Interdiction | 84 |
5.6. | Prosecuting Emerging Drug Cases | 87 |
5.7. | Crime Lab and Drug Testing | 88 |
5.8. | Emerging Drug Prevention | 89 |
5.9. | Future Directions | 90 |
| References | 92 |
| Index | 95 |